Indian Journal of Pharmacology Home 

LETTER TO THE EDITOR
[Download PDF]
Year : 2011  |  Volume : 43  |  Issue : 4  |  Page : 486-

Experimental evaluation of antipyretic and analgesic activities of aspartame

Kirtida R Tandel 
 Department of Pharmacology, Government Medical College, Surat, Gujarat, India

Correspondence Address:
Kirtida R Tandel
Department of Pharmacology, Government Medical College, Surat, Gujarat
India




How to cite this article:
Tandel KR. Experimental evaluation of antipyretic and analgesic activities of aspartame.Indian J Pharmacol 2011;43:486-486


How to cite this URL:
Tandel KR. Experimental evaluation of antipyretic and analgesic activities of aspartame. Indian J Pharmacol [serial online] 2011 [cited 2022 Jul 1 ];43:486-486
Available from: https://www.ijp-online.com/text.asp?2011/43/4/486/83131


Full Text

Sir,

The letter by Pradhan et al. [1] describes the experimental evaluation of antipyretic and analgesic activities of aspartame. I would like to draw attention to several points mentioned in this study.

In the methodology of the antipyretic activity, the authors have mentioned the doses of aspartame for groups II, III and IV and the dose of paracetamol for group V. But, they have not mentioned the route of administration for the same. The route of administration makes a difference in bioavailability and, hence, the effects and side-effects of a drug.

The authors have also mentioned earlier studies in which the anti-inflammatory action and interference with rheumatoid factor activity by aspartame has been proposed to alleviate the pain and immobility resulting from chronic inflammation of the joint. [2],[3] This can be a useful therapeutic approach for osteoarthritis or rheumatoid arthritis. But, some experimental studies show detrimental effects with the chronic use of aspartame. One of these studies show that aspartame is a multipotential carcinogenic compound whose carcinogenic effects are evident even at a daily dose of 20 mg/kg bw, much less than the current acceptable daily intake (ADI) for humans in Europe (40 mg/kg bw) and in the United States (50 mg/kg bw). [4] Hence, further exploration of toxicity studies is required for the long-term safety evaluation.

The authors while concluding have mentioned that aspartame is an intense nutritive sweetener. Although aspartame is a biologically active substance, it is not a nutritive substance. Actually, it is a non-nutritive intense sweetener that is considered as a food additive. A clarification of the above issues could enhance the scientific value of this research undertaken by the authors.

References

1Pradhan S, Shah UH, Mathur A, Sharma S. Experimental evaluation of antipyretic and analgesic activity of aspartame. Indian J Pharm 2011;43:89-90.
2Sharma S, Jain NK, Kulkarni SK. Possible analgesic and anti-inflammatory interactions of aspartame with opioids and NSAIDs. Indian J Exp Biol 2005;43:498-502.
3Ramsland PA, Movafagh BF, Reichlin M, Edmundson AB. Interference of rheumatoid factor activity by aspartame, a dipeptide methyl ester. J Mol Recognit 1999;12:249-57.
4Soffritti M, Belpoggi F, Degli Esposti D, Lambertini L, Tibaldi E, Rigano A. First experimental demonstration of the multipotential carcinogenic effects of aspartame administered in the feed to Sprague-Dawley rats. Environ Health Perspect 2006;114:379-85.